Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead remunerates USD 50 Million to collaborate with synthetic lethality startup Tango Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics. The deal provides Gilead with the option to receive the worldwide rights to five targets discovered and validated by Tango. The company, a Third Rock Ventures-backed startup that uses CRISPR and other tools to discover synthetic lethal gene pairs. The approach had opened more targets than the startup, driving it to enter into discussions with potential partners. Roche taps Halozyme’s drug delivery tech for up to USD 520 Million Roche and Halozy...